Inclusion Criteria:  Registered on the CR-HepB platform Requiring or receiving antiviral therapy using nucleoside (acid) analogues (recommended as the first-line therapy in the 2019 Chinese Guidelines for Chronic Hepatitis B Prevention and Treatment )  Diagnosed as compensatory hepatitis B cirrhosis, with the diagnostic criteria fitting any of the following criteria:  Diagnosis of Liver cirrhosis by histology; Varicose veins in Esophageal and/or gastric fundus indicated by endoscopy; Diagnosis of Liver cirrhosis by Imaging examination (abdominal ultrasound, CT, MRI) ; Liver elasticity measurement >12.0 kpa (ALT<5×ULN) Platelet PLT lower than the lower limit of normal value, and Serum albumin (ALB) lower than 35 g/L or international standardized ratio (INR) >1.3. Completing the informed consent form  Exclusion Criteria:  With any decompensated cirrhosis events, such as esophagogastric variceal rupture and bleeding, ascites, and hepatic encephalopathy; With any malignant tumor; With serious illness on any vital organs and systems, including heart, lungs, kidneys, and blood; Unsuitable for participating the study deemed by researchers;